Association of Chemotherapy Timing in Pregnancy With Congenital Malformation

Mathilde van Gerwen, Charlotte Maggen, Elyce Cardonick, Emma J. Verwaaijen, Marry van den Heuvel-Eibrink, Roman G. Shmakov, Ingrid Boere, Mina M. Gziri, Petronella B. Ottevanger, Christianne A.R. Lok, Michael Halaska, Long Ting Shao, Ilana Struys, Elisabeth M. van Dijk-Lokkart, Kristel van Calsteren, Robert Fruscio, Paolo Zola, Giovanna Scarfone, Frédéric Amant

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review


Chemotherapy puts a developing fetus at risk of teratogenic effects. The standard recommendation is that chemotherapy be administered after organogenesis is complete, however, the exact gestational age that chemotherapy can be administered safely and avoid causing congenital malformations remains unknown.
Original languageEnglish
Pages (from-to)732-733
Number of pages2
JournalObstetrical and Gynecological Survey
Issue number12
Publication statusPublished - Dec 2021


Dive into the research topics of 'Association of Chemotherapy Timing in Pregnancy With Congenital Malformation'. Together they form a unique fingerprint.

Cite this